Meet Mary
Learn how ENDRA is using ultrasound to help make difficult-to-diagnose diseases easier to find and treat.
WATCH THE VIDEO >Non-Alcoholic Fatty Liver Disease (NAFLD), an asymptomatic precursor to conditions like NASH, fibrosis, cirrhosis and cancer, has traditionally been difficult to identify and monitor. ENDRA is enhancing ultrasound to change that.
Non-Alcoholic Fatty Liver Disease—NAFLD—affects between 15–40% of the world’s population,driven by obesity, diabetes and Hepatitis-C.
The direct cost of NAFLD in the U.S. every year—largely driven by the downstream complications of the disease, including fibrosis, cirrhosis and cancer.
Right now, doctors and their patients must rely on invasive surgical biopsy or a costly MRI.
NAFLD will likely be the greatest root cause of liver transplants.The disease will be a true health crisis.
Learn how ENDRA is using ultrasound to help make difficult-to-diagnose diseases easier to find and treat.
WATCH THE VIDEO >Thankfully, a simple tool is on the horizon. ENDRA’s technology, TAEUS®, is designed to provide some of the capabilities of CT/MRI, but at a fraction of the cost and at the point of care, simply by plugging in to a conventional ultrasound machine.
“The ability to accurately quantify fat in the liver, at the point of care, with ENDRA’s TAEUS® ultrasound could be revolutionary.”
TAEUS®’ future potential goes beyond just a single application.
ENDRA is ultrasound like you’ve never seen it before.
Ten times as many ultrasound machines as CT/MRI machines worldwide
TAEUS® technology costs 50x less than MRI technology
No invasive surgical biopsy, no ionizing radiation, no risky contrast agents
Can be used at the point of patient care, providing answers more quickly and efficiently
|
ENDRA is certified to ISO 13485:2016 Learn More> |
ENDRA operates a Quality Management System which complies with the requirements of ISO 13485:2016 & EN ISO 13485:2016 for the following scope:
Certificate number: MD 697226
Effective Date: 2022-04-02
Expiry Date: 2025-04-01
